## IQV: IQVIA Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.95 indicates fundamental undervaluation. Quality metrics strong (ROE 19%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($214.48)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Avoiding Lag: Real-Time Signals in (IQV) Movement**
- Source: Stock Traders Daily | 20251210T061000 | Neutral | Relevance: 99%
-  This article discusses real-time AI-generated trading signals for Iqvia Holdings Inc. (NYSE: IQV), highlighting a potential weak near-term sentiment and a mid-channel oscillation pattern. It presents three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored to different risk profiles, offering targets and stop-loss levels. The analysis emphasizes an exceptional risk-reward short setup with significant downside potential versus limited risk, alongside multi-timeframe signal analysis.

**2. IQVIA Holdings amends credit agreement to refinance loans and reduce interest rates**
- Source: Investing.com | 20251209T221116 | Somewhat-Bullish | Relevance: 99%
- IQVIA Holdings Inc. announced amendments to its Fifth Amended and Restated Credit Agreement, refinancing existing term loans into new classes and consolidating revolving credit commitments. The restructuring also reduces the interest rate for U.S. dollar-denominated term A loans and revolving credit loans by removing the term SOFR credit spread adjustment. Furthermore, the Swiss and Japanese subsidiary borrowers are released from their obligations under the credit agreement.

**3. Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term**
- Source: www.sharewise.com | 20251209T145003 | Bullish | Relevance: 98%
-  IQVIA Holdings (IQV) is identified as a top momentum stock by Zacks, supported by its high Style Scores. The article highlights the Zacks Style Scores (Value, Growth, Momentum, and VGM) as tools to pick stocks with the best potential to beat the market when combined with the Zacks Rank. Despite a #3 (Hold) Zacks Rank, IQV boasts an "A" for both Momentum and VGM Style Scores, indicating strong short-term potential and overall attractiveness for investors.

**4. IQVIA Holdings Inc. $IQV Shares Sold by Quantbot Technologies LP**
- Source: MarketBeat | 20251209T120812 | Somewhat-Bullish | Relevance: 97%
-  Quantbot Technologies LP significantly reduced its stake in IQVIA Holdings Inc. ($IQV) by 54.3% in the second quarter, selling 8,552 shares and retaining 7,206 shares valued at approximately $1.14 million. Despite this, institutional investors collectively own about 89.62% of the company's stock, with several other firms increasing their positions. IQVIA recently exceeded Q2 earnings and revenue expectations, reporting $3.00 EPS and $4.10 billion in revenue, and analysts maintain a "Moderate Buy" rating with a target price of $241.44.

**5. Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term**
- Source: www.sharewise.com | 20251209T160817 | Bullish | Relevance: 97%
-  IQVIA Holdings (IQV) is identified as a top momentum stock due to its strong performance in Zacks Style Scores, specifically an A for Momentum and an overall VGM Score of A. The article highlights IQV's consistent earnings estimate revisions and its status as a #3 (Hold) on the Zacks Rank, making it an attractive option for investors focused on upward trends. IQVIA, a prominent player in the life sciences industry, is currently seeing upward revisions in its fiscal 2025 earnings estimates from analysts.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $265 | $250 | +6% |
| 2025-11-13 | BMO Capital | $260 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-11-13 | BMO Capital | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 1 ($5.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Insider selling cluster: $5.8M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.95 indicates undervaluation relative to growth. Forward P/E 17.5x stretched relative to 9% growth. Analyst sentiment positive (1 raises, avg +6%). Insider selling cluster ($5.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.5B |
| Beta | 1.37 |
| 52W Range | $134.65 - $234.30 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.95 |
| Forward P/E | 17.5 |
| Current P/E | 19.0 |
| YoY Growth | 8.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -1.3% (minimal 5-day change). Below STRENGTH zone by 5.3pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.2%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.01), momentum weakening. RSI neutral at 57.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.31% (CS: 36) | Neutral |
| RSI_14 | 56.6 | Neutral |
| MACD Histogram | -1.01 | Bearish |
| vs SMA20 | 1.008x | Above |
| vs SMA50 | 1.046x | Above |
| vs SMA200 | 1.248x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $225.98
- **Stop Loss:** $214.48 (5.1% risk)
- **Target:** $248.98 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 120
- **Position Value:** $27,117.60
- **Portfolio %:** 27.12%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*